Literature DB >> 1208762

Clinical studies with dopamine-receptor stimulants.

B Angrist, H Thompson, B Shopsin, S Gershon.   

Abstract

Oral administration of ET-495 was found to cause worsening of psychiatric status in 4 out of 7 schizophrenic patients, and to induce a paranoid state and a syndrome of auditory hallucinosis in 2 non-schizophrenics. These observations were compatible with the hypothesized role of dopamine in schizophrenia. However, these psychotogenic effects were far less dramatic than those noted in other studies with amphetamine, methylphenidate or L-Dopa. Possible explanations for this differing psychotogenic potency of receptor stimulators versus presynaptic agonists are presented. Intravenous ET-495 and apomorphine did not show psychotogenic effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1208762     DOI: 10.1007/bf00428906

Source DB:  PubMed          Journal:  Psychopharmacologia


  12 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo.

Authors:  Cullen L Schmid; Laura M Bohn
Journal:  J Neurosci       Date:  2010-10-06       Impact factor: 6.167

Review 3.  Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress.

Authors:  Anthony A Grace
Journal:  Neurotox Res       Date:  2010-02-09       Impact factor: 3.911

Review 4.  Dopamine receptor homooligomers and heterooligomers in schizophrenia.

Authors:  Melissa L Perreault; Brian F O'Dowd; Susan R George
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

5.  Parkinsonism by haloperidol and piribedil.

Authors:  G U Corsini; M Del Zompo; A Spissu; A Mangoni; G L Gessa
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

6.  Behavioral and neuroendocrine effects of low dose ET-495: antagonism by haloperidol.

Authors:  B Angrist; M Ain; J Rotrosen; S Gershon; F S Halpern; E J Sachar
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

Review 7.  The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

Authors:  R Miller
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 8.  Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor.

Authors:  L Leriche; J Diaz; P Sokoloff
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Dopaminergic agonist properties of ephedrine--theoretical implications.

Authors:  B Angrist; J Rotrosen; D Kleinberg; V Merriam; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1977-12-19       Impact factor: 4.530

10.  New detection of brain dopamine receptors with (3H)dihydroergocryptine.

Authors:  M Tittler; P Weinreich; P Seeman
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.